



Received on 02 June 2020; received in revised form, 10 October 2020; accepted, 03 May 2021; published 01 June 2021

## FORMULATION AND EVALUATION OF CIPROFLOXACIN HYDROCHLORIDE ENCAPSULATED LIPOSOMAL HYDROGEL FOR DERMAL ADMINISTRATION

Susanta Paul <sup>\*1</sup>, Anannya Bose Paul <sup>2</sup>, Subhabrota Majumdar <sup>3</sup>, Tathagata Roy <sup>1</sup>, Srikanta Chandra <sup>4</sup> and Victor Roy Chowdhury <sup>1</sup>

Department of Pharmaceutical Technology <sup>1</sup>, JIS University, Kolkata - 700109, West Bengal, India.

Seacom Pharmacy College <sup>2</sup>, Sankrail, Howrah - 711302, West Bengal, India.

Calcutta Institute of Pharmaceutical Technology & Allied Health Sciences <sup>3</sup>, Banitabla, Uluberia, Howrah-711316, West Bengal, India.

Jakir Hossain Institute of Pharmacy <sup>4</sup>, Miapur, Murshidabad - 742225, West Bengal, India.

### Keywords:

Liposome, Hydrogel, Ciprofloxacin hydrochloride, Topical administration, *in-vitro* skin permeation study

### Correspondence to Author:

**Susanta Paul**

Assistant Professor,  
Department of Pharmaceutical  
Technology, JIS University, Kolkata -  
700109, West Bengal, India.

**E-mail:** susanta.paul@jisuniversity.ac.in

**ABSTRACT:** The present work aims to formulation and characterization of a topical liposomal gel for ciprofloxacin hydrochloride. The drug lipid interaction studies were carried out by FTIR analysis, X-ray diffraction study, and DSC study, and no changes of physicochemical properties of ciprofloxacin were found. The thin-film hydration method was used for the preparation of liposomes consisting of phosphatidylcholine (PC) and cholesterol (CH). For hydrogel preparation, Carbopol 940 was used. The maximum entrapment efficiency of  $79.51 \pm 2.395$  was found from liposomes formulated with PC/CH at a weight ratio of 30:10 (batch number – F5), and by increasing cholesterol content above this limit, the encapsulation efficiency decreased. All the prepared formulations were found stable and the liposomal gel approach of ciprofloxacin hydrochloride showed better skin residential time than the marketed formulation. The *in-vitro* drug permeation was found to be around within the range of 0.194-0.319 over a period of 12 h for different batches. In conclusion, ciprofloxacin hydrochloride liposomal hydrogel is a smart and suitable drug delivery system for improving the topical bioavailability of ciprofloxacin hydrochloride to treat various skin disorders.

**INTRODUCTION:** The human skin is the largest organ of the body, which is making up 16% of total body weight and having a surface area of 1.8 m<sup>2</sup>. Due to the highly hydrophobic crystalline barrier of the skin, it generally limits the transdermal administration of several poorly soluble drugs <sup>1,2</sup>.

Poor bioavailability of the active pharmaceutical agent from various marketed conventional dosage forms is mainly due to the poor dermal penetration and insufficient residential time on the outermost part of the skin; thus, the therapeutic concentration of many drug substances cannot be achieved at the specific site of application <sup>3,4</sup>.

Fluoroquinolones are the group of antibacterial agents that have shown excellent activity against the most frequently occurring gram-positive and gram-negative ocular pathogens. Among other Fluoroquinolones, Ciprofloxacin is widely used against a broad spectrum of aerobic Gram-positive

<p><b>QUICK RESPONSE CODE</b></p> 	<p><b>DOI:</b> 10.13040/IJPSR.0975-8232.12(6).3249-56</p> <hr/> <p>This article can be accessed online on <a href="http://www.ijpsr.com">www.ijpsr.com</a></p> <hr/> <p>DOI link: <a href="http://dx.doi.org/10.13040/IJPSR.0975-8232.12(6).3249-56">http://dx.doi.org/10.13040/IJPSR.0975-8232.12(6).3249-56</a></p>
---	---

and Gram-negative bacteria<sup>5</sup>. Ciprofloxacin is a water-soluble drug and it is currently the drug of choice as an antibacterial agent for various skin infections like acne, skin rash. The bioavailability of the marketed conventional formulations is very poor so the frequent application is required to maintain therapeutic concentration which leads to poor patient compliance<sup>2</sup>.

To prolong the residential time and improve the bioavailability of ciprofloxacin, the introduction of smart drug delivery systems, including vesicular drug delivery systems, like liposomes have recently been proposed. Liposomes are microscopic bilayered vesicles in which an aqueous core is enclosed by a lipid bilayer having size ranges from 30 nm to several micrometers<sup>2,4</sup>. Liposomes can be prepared from various natural or synthetic phospholipids. A closed bilayer structure will form upon hydration of phospholipid in an aqueous solution. The property of liposomal vesicles totally depends on the composition of lipid, surface charge, size of the vesicles, and the method of preparations of the liposomes.

Liposomal drug delivery systems are the most promising approach for topical administration as they are biocompatible, and it can encapsulate both hydrophobic and hydrophilic drug substances due to the amphipathic property of phospholipids<sup>6</sup>. These artificial microscopic vesicles consist of one or more lipid bilayers surrounding aqueous part so that the liposomes are widely used as drug carriers for numerous active agents in cosmeceuticals and pharmaceutical Industries. The advantages of liposomes over other conventional topical formulations like ointments, gels, and creams that they can deliver the active drug substances into the cells or even inside individual cellular compartments, and by the liposomal drug delivery approach, the therapeutic index and efficacy of drugs can be increased.

Though it has some limitations like phospholipid undergoes oxidation and hydrolysis like reaction so they are prone to degrade and it has a shorter half-life, and due to having low viscosity it does not allow sufficient residential time at the site of application<sup>7,8</sup>. The viscosity of the liposome can be improved by incorporating the liposomes in biocompatible hydrogel matrices.

Besides, the liposomal hydrogel formulation of ciprofloxacin ensures a steady-state concentration for a prolonged period. It also makes intimate contact with the skin surface. The objective of the present work was to develop and evaluate topically effective prolonged-release of ciprofloxacin liposomal hydrogel formulation. The factors influencing the encapsulation of ciprofloxacin into liposomes were evaluated, and liposomal-based hydrogel was prepared with an optimized batch. The final liposomal hydrogel was evaluated for the *in-vitro* skin permeation study by using a Franz diffusion cell to investigate the permeation properties of ciprofloxacin from optimized liposomal hydrogel formulation<sup>8</sup>.

**MATERIALS:** Ciprofloxacin hydrochloride was procured from Alkem Laboratories Ltd, Sikkim, India, as a gift sample. Soy lecithin (Phosphatidylcholine) was purchased from Himedia, India. Cholesterol, Carbopol 940, and Triethanolamine were procured from Sigma-Aldrich, India. All other ingredients used in the study were of analytical grade. Double-distilled water was used throughout the experiments.

#### **METHODS:**

##### **Preparation of Liposomes with Ciprofloxacin**

**Hydrochloride:** Multilamellar liposomes were formulated by the thin film hydration method described by Berginc *et al.*, 2014. In brief, different molar ratios of phosphatidylcholine and cholesterol were accurately weighed and dissolved in chloroform: methanol mixture (2:1) in a round bottom flask.

The solvent was evaporated using a rotary evaporator (Cyberlab, US) system for at least 1 h at 40 °C. A formed thin film layer of lipid at the bottom of the flask was flushed under a stream of nitrogen for 1 min for the complete removal of the organic solvent part.

The remaining film was then hydrated in 20 mL of phosphate buffer (pH 7.4) containing accurately weighed ciprofloxacin hydrochloride. Small multilamellar vesicles were prepared after the sonication of large multilamellar vesicles for 10 min, using a bath sonicator. The liposomal suspensions were kept at 4 °C and protected from light<sup>6,8</sup>.

**TABLE 1: FORMULATION OF CIPROFLOXACIN HYDROCHLORIDE LIPOSOMES**

Formulation Code	Drug (mg)	Phosphatidylcholine (mg)	Cholesterol (mg)	Chloroform (ml)	Methanol (ml)
F <sub>1</sub>	100	10	10	20	10
F <sub>2</sub>	100	10	20	20	10
F <sub>3</sub>	100	20	10	20	10
F <sub>4</sub>	100	20	20	20	10
F <sub>5</sub>	100	30	10	20	10
F <sub>6</sub>	100	30	20	20	10

### Characterization of Prepared Liposomes:

#### Drug – Lipid Compatibility Studies:

**FTIR Analysis:** The only objective of this experiment was to evaluate whether there is any interaction between the lipid and ciprofloxacin hydrochloride. The compatibility between ciprofloxacin, cholesterol, and phosphatidylcholine was observed by FTIR analysis<sup>9,15</sup>.

**DSC Analysis:** DSC is an important analytical method to estimate phase transition temperature (T<sub>c</sub>). The temperature of maximal excess heat capacity was defined as the phase transition temperature. DSC analysis was performed with a differential scanning calorimeter (Pyris Diamond TG/DTA, Perkin Elmer, Singapore). Samples of pure ciprofloxacin hydrochloride, soya lecithin, cholesterol were submitted to DSC analysis. Accurately weighed samples were placed in aluminum sample pans. Platinum crucible used with alpha alumina powder was taken as a reference sample. Thermograms were discovered by heating the sample at a constant rate of 20 °C/min. A dry purge of nitrogen gas (20 ml/ min) was used for all runs. Samples were heated from 0 °C to 300 °C. Scans were obtained from the samples. The melting point, peak maxima, and the presence and absence of endotherm peaks were perceived in the DSC graphs<sup>9</sup>.

**X-ray Diffraction Study:** Samples of pure ciprofloxacin hydrochloride, soya lecithin, cholesterol were analyzed using an X-ray diffractometer (Ultima-iii, rigaku make, Japan) and the data were achieved from scans<sup>9</sup>.

**% Entrapment Efficiency (%EE):** Drug entrapment efficiency or percentage entrapment efficiency was calculated using the centrifugation method. The liposomal suspensions of 1 ml from different batches were taken and centrifuged at 3000 rpm for 10 min. The sediment obtained after the centrifugation process was suspended again in 100 ml of phosphate buffer pH 7.4, and the

absorbance was measured at 276 nm by using Shimadzu UV- 1700 Spectrophotometer, Tokyo, Japan. From the value of absorbance, the amounts present in 1 ml of liposomal suspensions were calculated. The % Entrapment Efficiencies were calculated from the below-mentioned formula<sup>9,10</sup>.

% of Entrapment Efficiency = Amount of Drug in the sediment / (Total amount of drug added) × 100

#### Determination of pH of Liposomal Gel

**Formulation:** The pH of different batches was experimentally evaluated by using a digital pH – meter (Sartorius, GD103, US)<sup>9,10</sup>.

**Percentage Yield of Liposomes:** After complete drying down, the drug-loaded liposomes were collected and weighed accurately. The yield of dried liposomes was determined by the following formula<sup>18-20</sup>.

% Yield = (Total weight of the dried liposomes (g)) / (Total weight of drug taken + Total weight of lipids) × 100

#### In-vitro Drug Release Study of Ciprofloxacin

**Liposome:** The release of ciprofloxacin hydrochloride from the prepared liposomal suspension was determined using the membrane diffusion technique. In this study, the dialysis tubing membrane having a molecular weight of 12000 previously pre-soaked overnight in phosphate buffer (pH 7.4) was used. An accurately weighed amount of ciprofloxacin hydrochloride liposomal suspension was placed in the dialysis tubing membrane, and the end part of the tube was sealed. The sealed parts of the tubes were placed in a conical flask containing 50 ml of phosphate buffer pH 7.4 in an orbital shaker incubator. The incubator was allowed to shake at 100 strokes per minute. The samples were withdrawn from a conical flask at a different time interval (1- 12 h). The dissolution medium was replaced with the same amount of fresh phosphate buffer (pH 7.4) solution. The absorbances of samples were recorded by using Shimadzu UV- 1700 Spectro-

photometer for drug content at 276 nm. The cumulative % of drug released was then calculated from the recorded values and plotted against time<sup>20</sup>.

### Preparation of Ciprofloxacin Loaded Liposomal Gel:

Carbopol 940 (0.5% w/w) was used as a gelling agent in order to prepare hydrogels for topical administration. Briefly, the gelling agent was first dispersed in phosphate buffer solution (pH 7.4) and allowed to hydrate overnight at room temperature for swelling the polymer. Then the optimized Liposomes containing ciprofloxacin hydrochloride were directly mixed into the previously prepared carbopol 940 gel by using a magnetic stirrer (2MLH, Remi lab instruments, Mumbai, India). The final product was then neutralized using triethanolamine (0.5% w/w).

### In-vitro Skin Permeation Study of Ciprofloxacin Loaded Liposomal Gel:

The *in-vitro* skin permeation study was carried out with a conventional Franz diffusion cell. For the *in-vitro* drug permeation study, goat skin was taken as a membrane. The skin was stored at 4 °C until the experiment after removal of hair from the skin, the skin was hydrated in normal saline, and the adipose tissue layer was removed from the skin by rubbing with a cotton swab. The goatskin was placed on the diffusion chamber, and the receptor compartment

was filled with 10 ml of phosphate buffer solution (pH 7.4), while an adequate quantity of liposomal hydrogel containing ciprofloxacin hydrochloride was applied to the epithelial side of the skin. The temperature in the diffusion chamber was maintained at 37 °C by a thermostatic water bath. The receptor buffer was removed 1, 2, 3, 4, 5, and up to 12 h and immediately replaced by previously aerated fresh phosphate buffer. The samples were analyzed spectrophotometrically for drug content at 276 nm. The experiments were performed in triplicates, and the results were represented as the mean values of three runs. The cumulative amount of ciprofloxacin permeated across the skin was estimated as a function of time<sup>11-13</sup>.

**RESULTS AND DISCUSSION:** The maximum absorbance of ciprofloxacin hydrochloride was found to be 276 nm, and a linear relationship was observed between the serial concentrations of ciprofloxacin hydrochloride prepared and the value of UV spectrophotometric absorption. Slope and regression were determined to be 0.10556 and 0.9908, respectively. The melting point of the ciprofloxacin hydrochloride powder was determined by using melting point apparatus. The melting point of ciprofloxacin hydrochloride was found to be 256 °C.





FIG. 1: FOURIER-TRANSFORM INFRARED SPECTROSCOPY PHOTOGRAPH OF CIPROFLOXACIN HYDROCHLORIDE, PHOSPHATIDYLCHOLINE AND CHOLESTEROL

FTIR and DSC On comparison of IR spectra of pure ciprofloxacin hydrochloride, soya lecithin, and cholesterol, it was clear that there are no possible physic-chemical interactions between the active drug substance and the other excipients Fig. 1. The


DSC results of pure drug, phosphatidylcholine and cholesterol suggest the excipients are compatible with the ciprofloxacin hydrochloride as there is no detectable endotherm when the ciprofloxacin hydrochloride present in the polymer mixtures Fig.

2. X-ray diffraction study has been widely used in the characterization for the detailing of critical features like crystal structure, crystallite size, and strain. While the diffraction pattern for pure ciprofloxacin hydrochloride shows various sharp


peaks but the diffraction patterns for dried liposomes did not show any peaks in the same region of the spectrum, which indicates the amorphous characteristic of dried liposomes **Fig. 3**.



**FIG. 2: DIFFERENTIAL SCANNING CALORIMETRY ANALYSIS OF PURE DRUG, PHOSPHATIDYLCHOLINE, CHOLESTEROL**



**FIG. 3: X-RAY SPECTRA OF PURE CIPROFLOXACIN HYDROCHLORIDE**



**FIG. 4: X-RAY SPECTRA OF DRIED LIPOSOME**

**% of Entrapment Efficiency:** The percentage entrapment efficiency of ciprofloxacin liposomal vesicles depends on the composition of lipids and the physico-chemical properties of the active drug agent.


The ciprofloxacin liposomes composed of phosphatidylcholine and Cholesterol in a molar ratio of 30:10 (F5) showed the optimum encapsulation efficiency, but further increase in cholesterol concentration decreased the entrapment efficiency.

**pH:** The pH values of all liposomal suspensions were found to be in the range from 3.13 to 3.69. The pH value of all formulations indicates no skin irritation. So the prepared liposomal hydrogel of ciprofloxacin is compatible with topical administration.

**Percentage Yield of Liposomes:** The percentage yield for the prepared ciprofloxacin hydrochloride encapsulated liposome was found to be in the range of 77.21–86.75%. The percentage yield of liposome formulations was increased with an increase in the molar ratio of phosphatidylcholine and cholesterol.

**TABLE 2: PERCENTAGE ENTRAPMENT EFFICIENCY OF CIPROFLOXACIN HYDROCHLORIDE IN LIPOSOMES, PERCENTAGE YIELD AND THE PH OF CIPROFLOXACIN HYDROCHLORIDE LIPOSOME**

Formulation Code	Entrapment efficiency (%)	Yield (%)	pH
F <sub>1</sub>	63.23±2.496	81.01±1.51	3.47±0.02
F <sub>2</sub>	67.24±2.029	83.51±1.03	3.13±0.10
F <sub>3</sub>	70.12±1.661	86.75±2.35	3.29±0.29
F <sub>4</sub>	74.87±1.851	83.81±0.78	3.13±0.31
F <sub>5</sub>	79.21±2.395	82.29±1.39	3.32±0.06
F <sub>6</sub>	76.42±2.444	77.21±2.02	3.69±0.09



**FIG. 5: PERCENT ENTRAPMENT EFFICIENCY OF CIPROFLOXACIN HYDROCHLORIDE IN LIPOSOME**

**TABLE 3: CUMULATIVE PERCENTAGE OF DRUG RELEASE OF CIPROFLOXACIN HYDROCHLORIDE FROM LIPOSOME**

Time (h)	Cumulative % of drug release (F <sub>1</sub> )	Cumulative % of drug release (F <sub>2</sub> )	Cumulative % of drug release (F <sub>3</sub> )	Cumulative % of drug release (F <sub>4</sub> )	Cumulative % of drug release (F <sub>5</sub> )	Cumulative % of drug release (F <sub>6</sub> )
0	0	0	0	0	0	0
1	2.56	4.25	5.34	4.13	2.37	3.15
2	5.38	9.18	8.59	7.92	4.26	6.29
3	8.14	15.19	11.82	12.72	8.1	12.28
4	14.57	20.41	15.94	19.2	12.92	18.8
5	20.29	24.9	19.77	26.28	19.84	25.72
6	27.82	33.02	22.67	31.01	27.25	29.17
7	34.71	36.41	27.52	34.71	30.81	32.2
8	44.69	38.49	32.96	37.28	35.56	36.41
9	49.8	42.42	39.41	41.95	39.1	39.8
10	55.36	48.38	43.59	47.03	43.48	42.01
11	60.23	57.38	49.63	52.87	48.8	45.64
12	64.29	62.29	57.39	57.26	56.61	50.09

**In-vitro Drug Release Study of Ciprofloxacin Liposome:** The cumulative percentage of ciprofloxacin hydrochloride release from the formulated ciprofloxacin hydrochloride liposome of different formulations in phosphate buffer solution (pH 7.4) is given in **Fig. 6**, as a function of

time **Table 3**. It was observed that an increase in the concentration of phosphatidylcholine further decreased the cumulative release of ciprofloxacin hydrochloride from liposomal suspension, indicating prolonged release of ciprofloxacin hydrochloride.




FIG. 6: IN-VITRO DRUG RELEASE OF CIPROFLOXACIN HYDROCHLORIDE FROM LIPOSOME

TABLE 4: CUMULATIVE AMOUNT OF PERMEATION OF CIPROFLOXACIN HYDROCHLORIDE LOADED LIPOSOMAL HYDROGEL

Time (Hr)	Cumulative amount of permeation (F <sub>1</sub> )	Cumulative amount of permeation (F <sub>2</sub> )	Cumulative amount of permeation (F <sub>3</sub> )	Cumulative amount of permeation (F <sub>4</sub> )	Cumulative amount of permeation (F <sub>5</sub> )	Cumulative amount of permeation (F <sub>6</sub> )	Cumulative amount of permeation (F <sub>7</sub> )
1	0.114	0.118	0.126	0.131	0.159	0.182	0.202
2	0.125	0.128	0.137	0.14	0.167	0.19	0.213
3	0.133	0.135	0.145	0.149	0.175	0.199	0.221
4	0.139	0.144	0.153	0.158	0.186	0.207	0.232
5	0.147	0.154	0.16	0.167	0.197	0.217	0.246
6	0.153	0.162	0.168	0.175	0.209	0.223	0.254
7	0.159	0.17	0.177	0.187	0.217	0.231	0.265
8	0.166	0.179	0.184	0.198	0.225	0.239	0.276
9	0.171	0.188	0.193	0.212	0.232	0.247	0.287
10	0.178	0.196	0.21	0.223	0.24	0.255	0.297
11	0.186	0.206	0.219	0.238	0.249	0.263	0.308
12	0.194	0.216	0.229	0.247	0.257	0.271	0.319




FIG. 7: IN-VITRO DRUG PERMEATION PROFILE OF DIFFERENT LIPOSOMAL HYDROGEL FORMULATIONS

**DISCUSSION:** In this work, it was found that as the phosphatidylcholine concentration was increased, it resulted in a corresponding increase in the encapsulation efficiency of ciprofloxacin hydrochloride in liposomal vesicles. An increase in total lipid concentration in liposome formulation was also able to control the release of the ciprofloxacin hydrochloride for prolonged period of time, which allows the sustained release characteristics of the different liposome formulations.

**In-vitro Drug Permeation Study:** The aim of this experiment was to estimate the permeation rate of liposome formulations as a transdermal dosage form.

The simplest way of topical application may be a direct spread of the ciprofloxacin hydrochloride liposomal hydrogel on the skin surface.

The cumulative amount of ciprofloxacin hydrochloride permeated from prepared liposomes to the receptor compartment is shown in **Table 4** and **Fig. 7**.

**CONCLUSION:** In conclusion, sustained delivery of ciprofloxacin hydrochloride can be obtained by the smart liposomal drug delivery system. Phospholipids are being a major component of the drug carrier system and can easily permeate through the tight epithelial junctions of the skin. Also, the desired hydration conditions can improve skin permeation. Hence as the concentration of phosphatidylcholine was increased, it would increase the penetration of ciprofloxacin hydrochloride. The introduction of liposomal drug delivery system has initiated a new approach in a novel drug delivery system for transdermal administration. Different reports show a promising future of liposomes in making transdermal delivery of various agents to treat some serious skin diseases.

**ACKNOWLEDGEMENT:** Nil

**CONFLICTS OF INTEREST:** The authors declare that the research was conducted in the

absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## REFERENCES:

1. Eman SE, Amna MM, Abeer MK and Doaa GH: Nanoemulsion gel of nutraceutical co-enzyme Q10 as an alternative to conventional topical delivery system to enhance skin permeability and anti-wrinkle efficiency. *Int J Pharm Pharm Sci* 2017; 9: 207-17.
2. Milla GB, Silvio AG, Camila MD, Larissa AR, Pedro JR and Ferdinando OC: Development and evaluation of stability of a gel formulation containing the Monoterpene Borneol. *Sci World J* 2016; 2016: 1-4.
3. Monika B, Szilvia B, Maria BS, Anita K and Erzsebet C: DSC for evaluating the encapsulation efficiency of lidocaine loaded liposomes compared to the ultracentrifugation method. *Journal of Thermal Analysis and Calorimetry* 2017; 130: 1619-25.
4. Zhengzi Q, Xianhuo W, Zheng S, Huilai Z, Shiyong Z and Jing Z: A Phase I Trial to evaluate the multiple-dose safety and antitumor activity of Ursolic acid liposomes in subjects with advanced solid tumors. *Bio Med Res Int* 2015; 2015: 1-7.
5. Foldvari M, Gesztes A and Mezei M: Dermal drug delivery by liposome encapsulation: clinical and electron microscopic studies. *J Microencapsul*. 1990; 7: 479-89.
6. Gyati S, Davinder S and Abhay A: Novel vesicular carriers for topical drug delivery and their applications. *International Journal of Pharmaceutical Sciences Review and Research* 2013; 21: 77-86.
7. Maximiliano G, Claudia S, Carlos B and Adriana MC: Percutaneous drug delivery systems for improving antifungal therapy effectiveness: A review. *International J of Pharmacy and Pharmaceutical Sciences* 2014; 6: 8-16.
8. El Maghraby GMM, Williams AC and Barry BW: Oestradiol skin delivery from ultra deformable liposomes: refinement of surfactant concentration. *Int J Pharm* 2000; 196: 63-74.
9. Dheeraj N, Nidhi A and Deepshikha K: Evaluation of liposomal gossypin in animal models of epilepsy. *Int J Pharm PharmSci* 2016; 8: 247-51.
10. Price CI, Horton JW and Baxter CR: Topical liposomal delivery of antibiotics in soft tissue infection. *J Surg Res* 1990; 49: 174-78.
11. Subash C and Pandey VP: Formulation and evaluation of Glimepiride-loaded liposomes by ethanol-injection method. *Asian J Pharm Clin Res* 2016; 9: 192-5.
12. Simons FER, Simons KJ and Frith EM: The pharmacokinetics and antihistaminic effects of the H1-receptor antagonist hydroxyzine. *J Allergy Clin Immunol* 1984; 73: 69-75.
13. Eskandar M, Mohsen T, Ali B and Somayeh H: Formulation and *in-vitro* evaluation of topical liposomal gel of triamcinolone acetonide. *Research Journal of Pharmaceutical, Biological and Chemical Sciences* 2013; 4: 101-7.
14. Foldvari M, Gesztes A and Mezei M: Dermal drug delivery by liposome encapsulation: clinical and electron microscopic studies. *J Microencapsul* 1990; 7: 479-89.
15. Patel HM and Moghimi SM: Liposomes and the skin permeability barrier. In: Gregoriadis G, Florence AT, Patel HM, eds. *Liposomes in Drug Delivery*. Chur, Switzerland: Harwood Academic Publishers 1993: 142-46.
16. Bashir SJ and Maibach HI: Cutaneous metabolism during *in-vitro* percutaneous absorption. In: Bronaugh RL, Kraeling MEK, Yourick J, Hood HL, eds. *Topical Absorption of Dermatological Products*. New York, NY: Marcel Dekker 2002: 77-81.
17. Balen GPV, Caron G, Ermondi G, Pagliara A, Grandi T, Bouchard G, Fruttero R, Carrupt PA and Testa B: Lipophilicity behavior of the zwitterionic antihistamine cetirizine in phosphatidylcholine liposomes/water systems. *Pharm Res*. 2001; 18: 694-01.
18. Price CI, Horton JW and Baxter CR: Topical liposomal delivery of antibiotics in soft tissue infection. *J Surg Res* 1990; 49: 174-78.
19. Akshay SR, Sudipta D and Arnab S: Design, formulation and evaluation of liposome containing isoniazid. *Int J Appl Pharm* 2018; 10: 52-6.
20. Yan L, Ruiyuan L, Jun Y, Yuanjie S, Guanghui M and Zhenzhong Z: Enhanced retention and anti-tumor efficacy of liposomes by changing their cellular uptake and pharmacokinetics behaviour. *Biomaterial* 2015; 41: 1-14.

### How to cite this article:

Paul S, Paul AB, Majumdar S, Roy T, Chandra S and Chowdhury VR: Formulation and evaluation of ciprofloxacin hydrochloride encapsulated liposomal hydrogel for dermal administration. *Int J Pharm Sci & Res* 2021; 12(6): 3249-56. doi: 10.13040/IJPSR.0975-8232.12(6).3249-56.

All © 2013 are reserved by the International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to **Android OS** based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)